Cancer-driving genomic aberrations in localized lung cancer appear are so consistently present across tumors that a single biopsy of one region of the tumor is likely to identify most of them, according to a new paper.
The study addresses the challenge of what scientists call genomic heterogeneity, the presence of many different variations that drive tumor formation, growth and progression, and likely complicate the choice and potential efficacy of therapy.
A landmark study of renal cell cancer in 2012 found that most cancer-promoting variations were not present across all regions of those tumors, so biopsy of a single region would not provide a good representation of cancer genes important in the genesis of any given tumor.